About Numedicus

About company

Numedicus’ approach to new products is based on therapeutic switches, namely new uses for known drugs, and alternatively called ‘drug reprofiling’, ‘drug repositioning’ or ‘drug repurposing’.Therapeutic switch projects are attractive because they can be commercialised more quickly, and with lower risk than medicines resulting from traditional approaches; they may also be underpinned by patents. Not only is there a greater chance of development succeeding but the R&D costs are a fraction of that incurred with a new chemical entity.